GLPG5201

GLPG5201, an anti-CD19/41BB CAR-T therapy, is administered as a fresh product following fludarabine/cyclophosphamide lymphodepleting chemotherapy. Upon screening, pts receive daily ibrutinib until leukapheresis...Median prior lines of therapy were 4 (range 2–10); 10/12 pts received a BTK inhibitor, 9/12 pts venetoclax, and 1 pt an allogeneic stem-cell transplant. Five of 7 pts with RT relapsed after, or were refractory to, R-CHOP...GLPG5201 demonstrates rapid in vivo expansion and durable persistence post-infusion. Euplagia-1 is ongoing, and updated data will be presented.

Following screening and enrollment, pts will receive daily ibrutinib continuously until mononuclear cell leukapheresis. During GLPG5201 manufacturing, pts receive cyclophosphamide (300 mg/m 2 /day)/fludarabine (30 mg/m 2 /day) for 3 days...GLPG5201 is a new CAR-T therapeutic option for pts with R/R CLL with or without RT, showing limited toxicity and promising efficacy based on current results (n=7). For all 7 pts, GLPG5201 was successfully manufactured at the PoC and administered as a fresh product, with a median vein-to-vein time of 7 days. Rapid complete responses have been observed with a 100% ORR in a heavily pre-treated pt population.